Biliary Atresia
63
17
18
22
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.8%
3 terminated out of 63 trials
88.0%
+1.4% vs benchmark
8%
5 trials in Phase 3/4
32%
7 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 22 completed trials
Clinical Trials (63)
Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary Atresia
Umbilical Cord Mesenchymal Stem Cell Therapy for Biliary Atresia
Mapping Disease Pathways for Biliary Atresia
Dry Blood Spot Screening Test for Biliary Atresia（DBS-SCReBA）
Molecular Characterization for Understanding Biliary Atresia
The Dirty Nappy Study
Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy
Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)
Biliary Atresia Research Network Northeast
Biliary Atresia Study in Infants and Children
A Prospective Database of Infants With Cholestasis
Preventive Effect of Prophylactic Oral Antibiotics Against Cholangitis After Kasai Portoenterostomy
Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
Tolerability of Enteral NAC in Infants
The Use of Near-Infrared Fluorescence Cholangiography With Indocyanine Green (ICG) in the Work Up of Neonatal Cholestasis
Kasai Portoenterostomy Timing and Outcomes in Biliary Atresia
Nutritional Intervention for Biliary Atresia
Stool Card in Biliary Atresia
Intestinal Microbiome Composition in Infants With Biliary Atresia (BA)